589 related articles for article (PubMed ID: 16569753)
1. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
Patel S; Hillard CJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):304-11. PubMed ID: 16569753
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety.
Antonelli T; Tomasini MC; Mazza R; Fuxe K; Gaetani S; Cuomo V; Tanganelli S; Ferraro L
J Pharmacol Exp Ther; 2009 May; 329(2):708-17. PubMed ID: 19197005
[TBL] [Abstract][Full Text] [Related]
4. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus.
Balázsa T; Bíró J; Gullai N; Ledent C; Sperlágh B
Neurochem Int; 2008 Jan; 52(1-2):95-102. PubMed ID: 17719142
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.
Zarrindast MR; Sarahroodi S; Arzi A; Khodayar MJ; Taheri-Shalmani S; Rezayof A
Behav Pharmacol; 2008 Oct; 19(7):716-23. PubMed ID: 18797248
[TBL] [Abstract][Full Text] [Related]
6. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum.
Wang X; Horswill JG; Whalley BJ; Stephens GJ
Mol Pharmacol; 2011 Apr; 79(4):758-67. PubMed ID: 21189269
[TBL] [Abstract][Full Text] [Related]
7. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
Hayase T
BMC Neurosci; 2007 Sep; 8():76. PubMed ID: 17877812
[TBL] [Abstract][Full Text] [Related]
8. Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng.
Park JH; Cha HY; Seo JJ; Hong JT; Han K; Oh KW
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):895-900. PubMed ID: 16002200
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.
Lake KD; Compton DR; Varga K; Martin BR; Kunos G
J Pharmacol Exp Ther; 1997 Jun; 281(3):1030-7. PubMed ID: 9190833
[TBL] [Abstract][Full Text] [Related]
10. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G; Mora F; Crossman AR; Brotchie JM
Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
[TBL] [Abstract][Full Text] [Related]
11. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors.
Urigüen L; Pérez-Rial S; Ledent C; Palomo T; Manzanares J
Neuropharmacology; 2004 Jun; 46(7):966-73. PubMed ID: 15081793
[TBL] [Abstract][Full Text] [Related]
12. Intra-periaqueductal gray matter injections of midazolam fail to alter anxiety in plus-maze experienced mice.
dos Reis LM; Canto-de-Souza A
Brain Res; 2008 Sep; 1231():93-102. PubMed ID: 18621039
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
14. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
[TBL] [Abstract][Full Text] [Related]
15. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
Fride E; Feigin C; Ponde DE; Breuer A; Hanus L; Arshavsky N; Mechoulam R
Eur J Pharmacol; 2004 Dec; 506(2):179-88. PubMed ID: 15588739
[TBL] [Abstract][Full Text] [Related]
16. Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats.
Hartmann A; Fassini A; Scopinho A; Correa FM; Guimarães FS; Lisboa SF; Resstel LB
J Psychopharmacol; 2019 May; 33(5):606-614. PubMed ID: 30789299
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle.
Lograno MD; Romano MR
Eur J Pharmacol; 2004 Jun; 494(1):55-62. PubMed ID: 15194451
[TBL] [Abstract][Full Text] [Related]
18. [Functional role of the endocannabinoid system in emotional homeostasis].
Marco EM; Viveros MP
Rev Neurol; 2009 Jan 1-15; 48(1):20-6. PubMed ID: 19145562
[TBL] [Abstract][Full Text] [Related]
19. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
[TBL] [Abstract][Full Text] [Related]
20. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
Hungund BL; Basavarajappa BS
Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
